Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAD17 pseudogene 1 (RAD17P1) is a non-coding genetic element classified as a pseudogene, meaning it shares sequence similarity with the functional RAD17 gene but lacks the ability to encode an active protein[1][2][3]. RAD17P1 is not known to have biological functions or disease associations, nor does it serve as a therapeutic target. Instead, RAD17P1 arose as a duplication of the RAD17 gene followed by loss of function due to mutations. In contrast, the parent gene, RAD17, encodes a critical enzyme in the DNA damage checkpoint, essential for genomic integrity and implicated in cancer biology[1][2][3]. RAD17P1 is often mentioned as part of gene annotations because the presence of pseudogenes can complicate genetic analyses, but by itself, it does not have a biological or therapeutic role. The entity “RAD17 pseudogene 1” is not a receptor, enzyme, transporter, or any other functional protein target. Structurally, it is a pseudogene, *not* an active gene product nor a therapeutic target; if you are seeking a target for drug discovery or biomarker research, refer to the functional gene RAD17[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAD17 pseudogene 1 (RAD17P1).